Is Afatinib used for lung Cancer?
Afatinib is an irreversibly binding second-generation EGFR tyrosine kinase inhibitor developed by Boehringer Ingelheim. It was first approved for marketing by the U.S. FDA on July 12, 2013, and then approved by the EMA for the treatment of advanced non-small cell lung cancer with EGFR sensitive mutations.
Visit: https://www.medixocentre.com/afatinib-cost
Like
Comment
Share
